U.S. markets close in 3 hours 1 minute

Fortress Biotech, Inc. (FBIO)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.6750-0.1550 (-5.48%)
As of 12:56PM EST. Market open.

Fortress Biotech, Inc.

2 Gansevoort Street
9th Floor
New York, NY 10014
United States
781 652 4500
http://www.fortressbiotech.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees93

Key Executives

NameTitlePayExercisedYear Born
Dr. Lindsay Allan RosenwaldExec. Chairman, Pres & CEO532.57kN/A1955
Mr. Michael S. WeissVice Chairman & Exec. Vice Chairman of Strategic Devel.532.57kN/A1966
Ms. Robyn M. HunterCFO, Treasurer & Corp. Sec.1.8MN/A1962
Mr. George C. AvgerinosSr. VP of Biologics Operations386.35kN/A1954
Dr. Thomas F. SchaibleProject Leader of Inflammatory Bowel DiseaseN/AN/AN/A
Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Fortress Biotech, Inc. develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Targadox for acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; Ximino to treat inflammatory lesions of severe acne vulgaris. It also develops MB-107, a gene therapy for X-linked severe combined immunodeficiency; CAEL-101, a Phase Ia/Ib trial product that reduces amyloid deposits in the tissues and organs; MB-102, a chimeric antigen receptor engineered T-cell (CAR T) program for acute myeloid leukemia; MB-106, a CAR T program for B cell non-Hodgkin lymphoma; and CS1 CAR T for multiple myeloma and light chain amyloidosis. In addition, the company develops MB-101 for Glioblastoma multiform (GBM); MB-103 for GBM, and breast cancer and brain metastases; MB 108 for GBM; MB-105 for prostate and pancreatic cancers; intravenous Tramadol for post-operative pain; CK-101 that is in Phase I/II clinical trial for treating patients with EGFR mutation-positive non-small cell lung cancer; Cosibelimab for metastatic cancer; Triplex, a Phase I study recombinant modified vaccinia ankara viral vector vaccine; ConVax, a recombinant modified vaccinia ankara viral vector vaccine; CEVA-101 for traumatic brain injury; CEVA-D, a bioreactor device that enhances the anti-inflammatory potency of bone marrow-derived cells; AVTS-001, an adeno-associated virus gene therapy; CUTX-101, a copper histidinate injection for the treatment of Menkes disease; CK-103 for metastatic solid tumor cancers; CK-302 for oncology indications; and CK-303 to treat renal cell carcinoma. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was founded in 2006 and is based in New York, New York.

Corporate Governance

Fortress Biotech, Inc.’s ISS Governance QualityScore as of November 1, 2019 is 6. The pillar scores are Audit: 2; Board: 9; Shareholder Rights: 2; Compensation: 7.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.